PL1928503T3
(en)
|
2005-08-24 |
2012-12-31 |
Immunogen Inc |
Process for preparing maytansinoid antibody conjugates
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US8183381B2
(en)
|
2007-07-19 |
2012-05-22 |
Metabolex Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
DE102008056086A1
(en)
*
|
2008-11-06 |
2010-05-12 |
Gp Solar Gmbh |
An additive for alkaline etching solutions, in particular for texture etching solutions and process for its preparation
|
AU2015224492B2
(en)
*
|
2009-02-05 |
2017-04-20 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
MX2011008328A
(en)
*
|
2009-02-05 |
2011-11-04 |
Immunogen Inc |
Novel benzodiazepine derivatives.
|
CN104984360A
(en)
|
2009-06-03 |
2015-10-21 |
伊缪诺金公司 |
Conjugation methods
|
FR2947269B1
(en)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
NEW ANTICANCER COMPOUNDS
|
FR2949469A1
(en)
*
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
|
CN102666553B
(en)
|
2009-10-01 |
2015-05-06 |
赛马拜制药公司 |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
JP5841072B2
(en)
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
CD20 antibody and use thereof
|
JP5870400B2
(en)
|
2010-04-15 |
2016-03-01 |
シアトル ジェネティクス,インコーポレーテッド |
Targeted pyrrolobenzodiazepine conjugates
|
BR112012026213B1
(en)
*
|
2010-04-15 |
2021-12-28 |
Medimmune Limited |
PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE
|
EP2789622B1
(en)
|
2010-04-15 |
2017-03-01 |
MedImmune Limited |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
CN103037843A
(en)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-Yl-phenoxymethyl)-thiazol-2-Yl]-piperidin-1-Yl}-pyrimidine
|
FR2963007B1
(en)
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
|
MX346635B
(en)
*
|
2011-02-15 |
2017-03-27 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives.
|
PT2691155T
(en)
|
2011-03-29 |
2019-02-19 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
US9156854B2
(en)
|
2011-04-18 |
2015-10-13 |
Immunogen, Inc. |
Maytansinoid derivatives with sulfoxide linker
|
CN103987718A
(en)
|
2011-09-20 |
2014-08-13 |
斯皮罗根有限公司 |
Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
|
SG11201401021TA
(en)
|
2011-10-14 |
2014-08-28 |
Spirogen Sarl |
Pyrrolobenzodiazepines
|
EP2751110B1
(en)
|
2011-10-14 |
2017-04-19 |
MedImmune Limited |
Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases
|
EP2753178B1
(en)
|
2011-10-14 |
2017-12-06 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
ES2687246T3
(en)
|
2011-10-14 |
2018-10-24 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and directed conjugates
|
EP2790724A4
(en)
*
|
2011-12-13 |
2015-08-05 |
Immunogen Inc |
Use of n-hydroxysuccinimide to improve conjugate stability
|
AR090549A1
(en)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
ANTI-LGR5 AND IMMUNOCATE PLAYERS
|
KR20150006000A
(en)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
Anti-pmel17 antibodies and immunoconjugates
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
EP2869849A1
(en)
|
2012-07-09 |
2015-05-13 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
EP2869850B1
(en)
|
2012-07-09 |
2017-08-23 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
US9464141B2
(en)
|
2012-08-02 |
2016-10-11 |
Genentech, Inc. |
Anti-ETBR antibodies and immunoconjugates
|
EP2887965A1
(en)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Cytotoxic benzodiazepine derivatives
|
AU2013326881B2
(en)
*
|
2012-10-04 |
2018-08-02 |
Immunogen, Inc. |
Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
|
JP6392764B2
(en)
|
2012-10-12 |
2018-09-19 |
エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugate
|
BR112015008238A2
(en)
|
2012-10-12 |
2017-11-28 |
Adc Therapeutics Sarl |
pyrrolbenzodiazepine-anti-cd22 antibody conjugates
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
CA2941485C
(en)
|
2012-10-12 |
2018-06-12 |
Philip Wilson Howard |
Pyrrolobenzodiazepines and conjugates thereof
|
EP2906297B1
(en)
|
2012-10-12 |
2017-12-06 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-antibody conjugates
|
CA2885305C
(en)
|
2012-10-12 |
2019-11-12 |
Spirogen Sarl |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
WO2014057113A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine - anti-psma antibody conjugates
|
TR201902494T4
(en)
|
2012-10-12 |
2019-03-21 |
Medimmune Ltd |
Pyrrolobenzodiazepines and their conjugates.
|
SI2906298T1
(en)
|
2012-10-12 |
2018-12-31 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2014080251A1
(en)
|
2012-11-24 |
2014-05-30 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
SG11201507214SA
(en)
*
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
DK2968494T3
(en)
|
2013-03-13 |
2019-03-04 |
Seattle Genetics Inc |
ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs
|
JP6340019B2
(en)
|
2013-03-13 |
2018-06-06 |
メドイミューン・リミテッドMedImmune Limited |
Pyrrolobenzodiazepine and its conjugates
|
KR20150127199A
(en)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Anti-b7-h4 antibodies and immunoconjugates
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2016001862A
(en)
|
2013-08-12 |
2016-08-03 |
Genentech Inc |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.
|
CN105518027A
(en)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
Methods of using anti-LGR5 antibodies
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110590950A
(en)
|
2013-12-13 |
2019-12-20 |
基因泰克公司 |
anti-CD 33 antibodies and immunoconjugates
|
JP6980384B2
(en)
|
2013-12-16 |
2021-12-15 |
ジェネンテック, インコーポレイテッド |
1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound, and methods of use and treatment
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
BR112016027222A2
(en)
|
2014-05-22 |
2018-01-30 |
Genentech Inc |
isolated antibodies, isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, methods of treating an individual with cancer, inhibiting cell proliferation, detecting human gpc3 and detecting a cancer
|
US20170260261A1
(en)
|
2014-08-28 |
2017-09-14 |
Bioatla, Llc |
Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
|
DK3189056T3
(en)
|
2014-09-03 |
2020-09-14 |
Immunogen Inc |
CYTOTOXIC BENZODIAZEPIN DERIVATIVES
|
US9381256B2
(en)
|
2014-09-03 |
2016-07-05 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EP3388449A3
(en)
|
2014-09-12 |
2018-10-24 |
F. Hoffmann-La Roche AG |
Cysteine engineered antibodies and conjugates
|
CN106804108B
(en)
|
2014-09-12 |
2021-08-10 |
基因泰克公司 |
anti-B7-H4 antibodies and immunoconjugates
|
CN114106185A
(en)
|
2014-09-12 |
2022-03-01 |
基因泰克公司 |
anti-HER 2 antibodies and immunoconjugates
|
CR20170095A
(en)
|
2014-09-12 |
2017-07-19 |
Genentech Inc |
ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS RECIPROCAL REFERENCES WITH RELATED APPLICATIONS
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3197500A1
(en)
*
|
2014-09-17 |
2017-08-02 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
AU2015352545B2
(en)
*
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
TW201632532A
(en)
|
2015-01-14 |
2016-09-16 |
必治妥美雅史谷比公司 |
Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
|
BR112017014599A2
(en)
|
2015-01-14 |
2018-01-16 |
Bristol-Myers Squibb Company |
benzodiazepine dimers, conjugates thereof, and methods of preparation and use
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
AU2016284340A1
(en)
|
2015-06-23 |
2018-02-08 |
Bristol-Myers Squibb Company |
Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
|
AU2015242213A1
(en)
|
2015-07-12 |
2018-03-08 |
Hangzhou Dac Biotech Co., Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
LT3325483T
(en)
|
2015-07-21 |
2020-01-27 |
Immunogen, Inc. |
Methods of preparing cytotoxic benzodiazepine derivatives
|
MA43354A
(en)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
|
WO2017107817A1
(en)
*
|
2015-12-21 |
2017-06-29 |
江苏恒瑞医药股份有限公司 |
Preparation method for antibody drug conjugate
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
MX2018012418A
(en)
|
2016-04-15 |
2019-07-10 |
Bioatla Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof.
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
LT3455261T
(en)
|
2016-05-13 |
2022-11-10 |
Bioatla, Inc. |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
CN107469089B
(en)
*
|
2016-06-07 |
2022-01-07 |
北京键凯科技股份有限公司 |
PEG connector and aglucon drug conjugate
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
WO2018026533A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
WO2018026890A1
(en)
|
2016-08-03 |
2018-02-08 |
Cymabay Therapeutics |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
EP3496763A1
(en)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
KR102345175B1
(en)
|
2016-11-14 |
2021-12-31 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
Binding linkers, cell binding molecule-drug conjugates containing such binding linkers, preparation and use of such conjugates with linkers
|
EP4015532A1
(en)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
EP3544983A2
(en)
|
2016-11-23 |
2019-10-02 |
Immunogen, Inc. |
Selective sulfonation of benzodiazepine derivatives
|
CA3045902A1
(en)
|
2016-12-21 |
2018-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
PT3558391T
(en)
|
2016-12-23 |
2022-05-05 |
Immunogen Inc |
Immunoconjugates targeting adam9 and methods of use thereof
|
TW201825515A
(en)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met antibodies and immunoconjugates and uses thereof
|
LT3544636T
(en)
|
2017-02-08 |
2021-06-25 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
HUE059828T2
(en)
|
2017-04-18 |
2023-01-28 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
EP3612234B1
(en)
|
2017-04-20 |
2024-03-13 |
ADC Therapeutics SA |
Combination therapy with an anti-axl antibody-drug conjugate
|
WO2018195243A1
(en)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and conjugates thereof
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
BR112019026564A2
(en)
|
2017-06-14 |
2020-06-30 |
Adc Therapeutics Sa |
dosing regimens for administration of an anti-cd19 adc
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human mesothelin antibodies and uses in cancer therapy
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
AU2018316532B2
(en)
|
2017-08-18 |
2022-11-24 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
EP3690038A4
(en)
|
2017-09-29 |
2021-05-19 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
US11793885B2
(en)
|
2017-12-28 |
2023-10-24 |
Immunogen, Inc. |
Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2020014482A1
(en)
|
2018-07-12 |
2020-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
US12012463B2
(en)
|
2018-08-08 |
2024-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
TW202029980A
(en)
|
2018-10-26 |
2020-08-16 |
美商免疫遺傳股份有限公司 |
Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof
|
KR20240015162A
(en)
|
2018-12-21 |
2024-02-02 |
어비디티 바이오사이언시스 인크. |
Anti-transferrin receptor antibodies and uses thereof
|
WO2020141923A2
(en)
*
|
2019-01-03 |
2020-07-09 |
주식회사 레고켐 바이오사이언스 |
Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
|
CN113490510A
(en)
|
2019-01-08 |
2021-10-08 |
美国政府(由卫生和人类服务部的部长所代表) |
Cross-species single domain antibodies targeting mesothelin for the treatment of solid tumors
|
EP3883971A1
(en)
|
2019-01-22 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
EP3918323A4
(en)
|
2019-01-30 |
2022-12-28 |
TrueBinding, Inc. |
Anti-gal3 antibodies and uses thereof
|
EP3947395A1
(en)
|
2019-03-29 |
2022-02-09 |
ImmunoGen, Inc. |
Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
|
EP4031250A1
(en)
|
2019-10-22 |
2022-07-27 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
US20230032465A1
(en)
|
2019-12-12 |
2023-02-02 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
AU2021237465A1
(en)
|
2020-03-19 |
2022-10-13 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
JP2023527638A
(en)
|
2020-03-27 |
2023-06-30 |
アビディティー バイオサイエンシーズ,インク. |
Compositions and methods for treating facioscapulohumeral muscular dystrophy
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
AU2022291120A1
(en)
|
2021-06-09 |
2023-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
WO2023288252A1
(en)
|
2021-07-13 |
2023-01-19 |
Truebinding, Inc. |
Methods of preventing protein aggregation
|
CA3231330A1
(en)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|